

# **PRESS RELEASE**

## **FULCRUM PHARMA PLC**

("the Company")

### **Appointment of new CEO**

Further to the announcement made on 10 January 2008, Fulcrum Pharma plc (AIM: FUL), the drug development and regulatory services company, announces that it has today appointed Dr Frank Armstrong as its new Chief Executive Officer as of 1<sup>st</sup> April 2008.

Dr. Armstrong has more than 20 years of experience at major pharmaceutical and leading biotechnology companies where he has been integral in bringing new pharmaceutical products to the market.

Most recently, Dr. Armstrong was President and Chief Executive Office of CuraGen Corporation, a NASDAQ listed biopharmaceutical company, from March 2006 until September 2007. Prior to CuraGen, Dr. Armstrong was CEO of Bioaccelerate Holdings Inc., Provensis Ltd. and Phoqus Pharmaceuticals plc. From 1998 to 2001, Dr. Armstrong was Executive Vice President and Head of Worldwide Product Development for Bayer AG, Germany, and from 1985 to 1998 served in various roles with ICI Pharmaceuticals, then Zeneca in the UK and USA where his final position was Senior Vice President of the Medical Research and Communications Group.

Dr. Armstrong received his MBChB from the University of Edinburgh and became a member of the Royal College of Physicians in 1984. He was elected a Fellow of the Royal College of Physicians, Edinburgh, in 1993 and elected a Fellow of the Faculty of Pharmaceutical Physicians in 1994.

Dr. Jon Court, the current CEO, will work closely with Dr Frank Armstrong and the senior management team at Fulcrum in his new role as director of Strategic Business Development.

#### **For further information, please contact:**

##### **Fulcrum Pharma PLC**

Geoffrey Smith, Finance Director	Tel: 01442 283600
David Kelly, Communications Executive	Tel: 0118 989 5680

##### **About Fulcrum Pharma plc**

Fulcrum Pharma plc is a drug development and regulatory services business that provides global expertise to achieve drug development and regulatory approval milestones. Fulcrum Pharma offers immediate access to a highly credible, integrated development team that provides strategic and operational leadership required to ensure that new drugs move smoothly from discovery research to product approval.

Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange having successfully floated in March 2000.

Date of Issue: Monday 10<sup>th</sup> March 2008